CAMP (Camp4 Therapeutics) 5-Year RORE % : 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAMP Camp4 Therapeutics Corp CAMP
8 GF Score
Price $4.49
! 4 Warning Signs
View Full Analysis

What is Camp4 Therapeutics 5-Year RORE %?

Camp4 Therapeutics CAMP +0.67% 8 5-Year RORE % is 0.00 as of Jun. 2026. GuruFocus rates CAMP with a GF Score™ of 8/100. The stock has 4 warning signs investors should review. Among 1,152 Biotechnology companies, Camp4 Therapeutics ranks worse than 86805.47% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Camp4 Therapeutics does not have enough data to calculate 5-Year RORE %.


Camp4 Therapeutics  (NAS:CAMP) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Camp4 Therapeutics 5-Year RORE % Related Terms


Camp4 Therapeutics 5-Year RORE % Historical Data

* Premium members only.

The historical data trend for Camp4 Therapeutics's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Camp4 Therapeutics 5-Year RORE % Chart

Camp4 Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
5-Year RORE %
0.00 0.00 0.00 0.00

Camp4 Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CAMP vs ALEC, ORMP, PYXS: 5-Year RORE % Comparison

For the Biotechnology subindustry, Camp4 Therapeutics's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Camp4 Therapeutics 5-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camp4 Therapeutics's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Camp4 Therapeutics's 5-Year RORE % falls into.


CAMP
8GF Score
Camp4 Therapeutics Corp CAMP
5-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Camp4 Therapeutics 5-Year RORE % Calculation

Camp4 Therapeutics's 5-Year RORE % for the quarter that ended in Jun. 2026 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( - )/( - )
=/
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 5-year before.

Frequently Asked Questions Learn more about 5-Year RORE % →
What does a 5-Year RORE % of 0.00 mean?
Camp4 Therapeutics (CAMP) has a 5-Year RORE % of 0.00 as of Jun. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Camp4 Therapeutics and its competitors. According to the industry distribution chart, Camp4 Therapeutics ranks #999999 out of 1152 companies in the Biotechnology industry.
Is Camp4 Therapeutics' 5-Year RORE % too high?
Camp4 Therapeutics' current 5-Year RORE % is 0.00. Based on the distribution chart, Camp4 Therapeutics ranks #999999 out of 1152 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Camp4 Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Camp4 Therapeutics' 5-Year RORE % compare to ALEC and ORMP?
According to the Biotechnology industry distribution chart, Camp4 Therapeutics ranks #999999 out of 1152 companies for 5-Year RORE %. This places Camp4 Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Biotechnology company?
A good 5-Year RORE % depends on the Biotechnology industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Camp4 Therapeutics and its competitors. Camp4 Therapeutics's current 5-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camp4 Therapeutics stock overvalued right now?
Camp4 Therapeutics (CAMP) has a current 5-Year RORE % of 0.00. The current 5-Year RORE % is 0.00. Camp4 Therapeutics' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Camp4 Therapeutics (CAMP), the current 5-Year RORE % is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Camp4 Therapeutics Business Description

Address One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, USA, 02139
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
8GF Score

Get the complete analysis for CAMP

5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.49
Price